Medical Consumables and Lab Consumables OEM Manufacturer
Medical Consumables and Lab Consumables OEM Manufacturer

News & Events

11 2026.01
Johnson & Johnson Reaches Drug Pricing Deal with U.S. Government
Johnson & Johnson has reached an agreement with the U.S. government to lower prices on select prescription drugs, marking a significant development in ongoing negotiations between the pharmaceutic...
09 2026.01
Variant Bio Launches AI-Powered Platform to Accelerate Drug Discovery Using Genetic Data
January 6, 2026 — Boston — Biotech company Variant Bio announced on Tuesday the launch of a new artificial intelligence-driven platform designed to accelerate the discovery and development of new dr...
06 2026.01
First-of-Its-Kind Fentanyl Vaccine Prepares to Enter Human Clinical Trials
January 2026 — Houston / Amsterdam A first-of-its-kind vaccine designed to prevent fatal fentanyl overdoses is preparing to enter its initial human clinical trials, marking a potential breakthrough i...
30 2025.12
FDA Approves Omeros’ Yartemlea as First Treatment for Transplant-Associated Thrombotic Microangiopathy
Washington, Dec. 24, 2025 — The U.S. Food and Drug Administration has approved Yartemlea, a monoclonal antibody developed by Omeros Corporation, as the first treatment for transplant-associated throm...
26 2025.12
UAE Becomes Second Country to Approve Gene Therapy Itvisma for Spinal Muscular Atrophy
The United Arab Emirates has become the second country in the world to approve the gene therapy Itvisma for the treatment of spinal muscular atrophy (SMA), marking another milestone in the global adop...
23 2025.12
Sanofi Signs Up to $1.04 Billion Alzheimer’s Drug Development Deal with South Korea’s ADEL
Paris / Seoul — Dec. 15, 2025 — French pharmaceutical company Sanofi has entered into a strategic collaboration with South Korean biotech firm ADEL worth up to USD 1.04 billion to jointly develop an...
19 2025.12
FDA Approves BioCryst’s Oral Pellet Form of Orladeyo, First Oral Prophylactic Therapy for Children Aged 2–11 with HAE
Durham, NC — Dec. 12, 2025 — The U.S. Food and Drug Administration (FDA) has approved an oral pellet formulation of Orladeyo (berotralstat) from BioCryst Pharmaceuticals for prophylactic use in chil...
16 2025.12
FDA Approves First Gene Therapy for Rare Immune Disorder Wiskott-Aldrich Syndrome, Expanding Treatment to Patients Aged 6 Months and Older
Washington, Dec. 9, 2025 — The U.S. Food and Drug Administration (FDA) has approved Waskyra (etuvetidigene autotemcel), a gene therapy developed by nonprofit organization Fondazione Telethon ETS, for...
12 2025.12
Vertex’s Gene Therapy Casgevy Shows Strong Efficacy in Younger Children with Blood Disorders
Boston, December 6, 2025Vertex Pharmaceuticals announced new clinical data demonstrating that its gene-editing therapy Casgevy (exagamglogene autotemcel, exa-cel) produced robust therapeutic benefits ...
09 2025.12
Capricor Reports Positive Phase 3 HOPE-3 Results: Deramiocel Demonstrates Skeletal and Cardiac Benefits in Duchenne Muscular Dystrophy
December 3, 2025 — Capricor Therapeutics announced that its investigational cell therapy Deramiocel achieved both primary and key secondary endpoints in the pivotal Phase 3 HOPE-3 trial for Duchenne ...
05 2025.12
Regeneron and Tessera Therapeutics Partner to Develop in-Vivo Gene Editing Therapy TSRA-196 for Alpha-1 Antitrypsin Deficiency
December 1, 2025 — Regeneron Pharmaceuticals announced today a global collaboration with Tessera Therapeutics to develop and commercialize Tessera’s investigational in-vivo gene editing therapy TSRA...
02 2025.12
Genentech to Present 46 Hematology Abstracts at ASH 2025, Including New AAV Gene Therapy and Oncology Data
South San Francisco, CA — November 3, 2025 — Biotech leader Genentech announced that it will present 46 abstracts, including 12 oral presentations, from its hematology portfolio at the upcoming ASH ...